CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Preclinical studies on Myrcludex B, a novel Hepatitis B virus (HBV)-envelope protein derived entry inhibitor
DOI 10.1055/s-0029-1246535
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Schulze, A Schieck, C Gähler, A Meier, T Müller, A Alexandrov, W Mier, S Urban
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
The approved treatment options for chronic hepatitis B consist either of inhibition of HBV genome replication by nucleoside or non-nucleoside reverse transcriptase (RT) inhibitors or stimulation of innate or adaptive immune responses e.g. by interferon α. However, although these drugs can reduce the HBV serum titers significantly, an elimination of the virus is commonly not achieved. Furthermore, virus replication i…
Zitieren
Zitierempfehlung
A Schulze, A Schieck, C Gähler, A Meier, T Müller, A Alexandrov, W Mier, S Urban (2010) Preclinical studies on Myrcludex B, a novel Hepatitis B virus (HBV)-envelope protein derived entry inhibitor. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0029-1246535
Mit CareLit weiterarbeiten